A Bioelectronic Sensor for Rapid Assessment of Antibody Titer and Glycan Structure
This project will result in a scalable, microfluidic system for rapid and informative analytical measurements that will bolster the development of vaccines and therapeutics for coronavirus.
Categories
Proteins/ Antibodies
Vaccines
Process control
Industry Need
The biomanufacturing industry would benefit from rapid, scalable, and informative analytical measurements for use during biologics production that would speed up the development and production of vaccines and therapeutics.
Solution
The University of Maryland, College Park, aimed to develop a microfluidic analytic devicefor the rapid quantification of antibody titer and N-linked galactosylation. The device is integrated with bioelectronic sensor technology that can quickly inform the total proportion of galactosylated antibodies in a sample. If successful, this device would reduce cost and time associated with the development and production processes of biologics by generating rapid analysis of vital analytical features of antibody therapeutics.
Outputs/Deliverables
Development of an integrated device and sensor technology that can rapidly assess antibody titer and glycan structure, addressing the need for a rapid and low-cost method to monitor, measure, and characterize critical process parameters and critical quality attributes during manufacturing and production
A 3D printed microfluidic device to house the sensor technology
Current responses were consistent, rapid, reproducible, and distinguishable; current responses were also able to be restored following regeneration. Thus, the sensing surfaces were reusable.
Additional Project Information (Members Only)
Login to the NIIMBL member portal to access more, including: